4/24
03:39 pm
tvtx
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at HC Wainwright from $17.00 to $19.00. They now have a "buy" rating on the stock.
Low
Report
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at HC Wainwright from $17.00 to $19.00. They now have a "buy" rating on the stock.
4/24
07:05 am
tvtx
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Medium
Report
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
4/24
05:34 am
tvtx
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Medium
Report
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
4/24
03:08 am
tvtx
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy [Yahoo! Finance]
Medium
Report
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy [Yahoo! Finance]
4/24
03:00 am
tvtx
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Medium
Report
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
4/24
03:00 am
tvtx
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Medium
Report
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
4/7
09:13 pm
tvtx
Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan [Yahoo! Finance]
Low
Report
Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan [Yahoo! Finance]
4/4
04:45 pm
tvtx
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International [Yahoo! Finance]
Low
Report
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International [Yahoo! Finance]
4/4
04:30 pm
tvtx
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
Low
Report
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
4/4
12:08 pm
tvtx
OUTbio San Diego Celebrates First Anniversary: A Year of Empowerment and Inclusion for LGBTQ+ Life Science Professionals in San Diego [Yahoo! Finance]
Low
Report
OUTbio San Diego Celebrates First Anniversary: A Year of Empowerment and Inclusion for LGBTQ+ Life Science Professionals in San Diego [Yahoo! Finance]
4/3
04:54 pm
tvtx
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association [Yahoo! Finance]
Low
Report
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association [Yahoo! Finance]
4/3
04:30 pm
tvtx
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
Low
Report
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
3/27
08:07 am
tvtx
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its "neutral" rating re-affirmed by analysts at Guggenheim.
Medium
Report
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its "neutral" rating re-affirmed by analysts at Guggenheim.
3/18
03:15 pm
tvtx
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Low
Report
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
3/13
05:00 pm
tvtx
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/11
07:35 am
tvtx
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN) [Yahoo! Finance]
Medium
Report
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN) [Yahoo! Finance]
3/11
07:05 am
tvtx
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Medium
Report
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
2/26
04:30 pm
tvtx
Travere Therapeutics to Present at Upcoming Investor Conferences
Medium
Report
Travere Therapeutics to Present at Upcoming Investor Conferences
2/23
07:23 am
tvtx
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy [Yahoo! Finance]
Medium
Report
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy [Yahoo! Finance]
2/23
07:05 am
tvtx
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
Low
Report
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
2/23
02:08 am
tvtx
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy [Yahoo! Finance]
Low
Report
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy [Yahoo! Finance]
2/23
02:00 am
tvtx
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
Low
Report
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
2/23
02:00 am
tvtx
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
Low
Report
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy
2/16
02:36 pm
tvtx
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Wells Fargo & Company from $8.00 to $9.00. They now have an "equal weight" rating on the stock.
Low
Report
Travere Therapeutics, Inc. (NASDAQ: TVTX) had its price target raised by analysts at Wells Fargo & Company from $8.00 to $9.00. They now have an "equal weight" rating on the stock.
2/16
10:12 am
tvtx
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]